评估 Zr-89、Sm-153 和 Lu-177 医用放射性同位素的吸收剂量：IDAC-Dose2.1 和 OLINDA 经验。

Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.

机构信息

Minia University, Faculty of Science, Department of Physics, El-Minia, Egypt; Institute of Physics and Technology, Ural Federal University, Yekaterinburg, 620002, Russian Federation.

Institute of Physics and Technology, Ural Federal University, Yekaterinburg, 620002, Russian Federation; Physics Department, Faculty of Science, Al-Azhar University, Assuit Branch, 71524, Assuit, Egypt.

出版信息

Appl Radiat Isot. 2021 Oct;176:109841. doi: 10.1016/j.apradiso.2021.109841. Epub 2021 Jun 26.

DOI:10.1016/j.apradiso.2021.109841

PMID:34214913

Abstract

OBJECTIVE

In this article, IDAC-Dose2.1 and OLINDA computer codes are compared as they are the most widely used software tools for internal dosimetry assessment at the present time. OLINDA/EXM personal computer code was created as a replacement for the widely used MIRDOSE3.1 code. IDAC-Dose2.1 was developed based on the ICRP specific absorbed fractions and computational framework of internal dose assessment given for reference adults in ICRP Publication 133. IDAC uses cumulated activities per administered activity in hours and calculates the absorbed dose and the effective dose. The program calculates the dose in the Eckerman stylized family phantoms. It is useful in standardizing and automating internal dose calculations, assessing doses in clinical trials with radiopharmaceuticals, making theoretic calculations for existing pharmaceuticals, teaching, and other purposes.

METHODS

To produce such a comparison, the results of this work were compared with available published data in the literature on radiopharmaceuticals. Radiopharmaceuticals with Zr, Sm, Lu radionuclides are used as the basis for the comparison. Zr, Sm, Lu radionuclides are regarded as the future of radiopharmaceutical treatment. For Zr, two different labelled carriers, Zr-89_cMAb U36 and Zr-89 Panitumumab, were used on patients.

RESULTS

The results show a clear difference in terms of absorbed dose of the Zr-89 radiopharmaceuticals for red bone marrow when calculated by IDAC-Dose2.1 (0.76 mGy/MBq), while the estimated absorbed dose in literature results is 0.07 mGy/MBq and 0.14 mGy/MBq when the calculation is done by OLINDA program. In the case of Lu-EDTMP, the absorbed dose in red bone marrow is in reasonable agreement (0.63 mGy/MBq and 0.8 mGy/MBq for IDAC-Dose2.1 and OLINDA, respectively). A significant difference was found for the absorbed dose in the bone surface, which was almost twice as high for OLINDA (2.1 mGy/MBq for IDAC-Dose2.1 and 5.4 mGy/MBq for OLINDA). In some direct cases, the calculated absorbed dose in the urinary bladder wall with OLINDA is ten times higher compared to WinAct (which was utilized to calculate the total activity in the organs and tissues) and IDAC 2.1. These results are considered key to greater accuracy in internal dose calculation.

摘要

目的

本文比较了 IDAC-Dose2.1 和 OLINDA 计算机代码，因为它们是目前最广泛用于内部剂量评估的软件工具。OLINDA/EXM 个人计算机代码是作为广泛使用的 MIRDOSE3.1 代码的替代品而创建的。IDAC-Dose2.1 是基于 ICRP 特定的吸收分数和 ICRP 出版物 133 中为参考成年人提供的内部剂量评估计算框架开发的。IDAC 使用每小时给予的活动的累积活性来计算吸收剂量和有效剂量。该程序计算 Eckerman 风格化家族体模中的剂量。它可用于标准化和自动化内部剂量计算、评估放射性药物临床试验中的剂量、对现有药物进行理论计算、教学和其他用途。

方法

为了进行这样的比较，将这项工作的结果与放射性药物文献中的可用已发表数据进行了比较。使用 Zr、Sm、Lu 放射性核素的放射性药物作为比较的基础。Zr、Sm、Lu 放射性核素被视为放射性药物治疗的未来。对于 Zr，两种不同的标记载体，Zr-89_cMAb U36 和 Zr-89 帕尼单抗，被用于患者。

结果

结果表明，当通过 IDAC-Dose2.1（0.76 mGy/MBq）计算时，Zr-89 放射性药物对红骨髓的吸收剂量有明显差异，而文献结果中的估计吸收剂量为 0.07 mGy/MBq 和 0.14 mGy/MBq 当通过 OLINDA 程序计算时。在 Lu-EDTMP 的情况下，红骨髓中的吸收剂量是合理一致的（IDAC-Dose2.1 为 0.63 mGy/MBq，OLINDA 为 0.8 mGy/MBq）。骨表面的吸收剂量有显著差异，OLINDA 几乎高出两倍（IDAC-Dose2.1 为 2.1 mGy/MBq，OLINDA 为 5.4 mGy/MBq）。在一些直接的情况下，与 WinAct（用于计算器官和组织中的总活性）和 IDAC 2.1 相比，OLINDA 计算的膀胱壁吸收剂量高出十倍。这些结果被认为是内部剂量计算更准确的关键。